Navigation Links
Molecular Devices Releases Breakthrough TUNE Technology, Now Part of the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform
Date:9/2/2011

SUNNYVALE, Calif., Sept. 2, 2011 /PRNewswire/ -- Today, Molecular Devices, a leading provider of instruments, software, and consumables for drug discovery and life sciences research, announced the addition of the TUNE detection cartridge to the SpectraMax Paradigm Multi-Mode Microplate Detection Platform. The breakthrough technology of TUNE with wavelength flexibility in a monochromator device and up to 10x the sensitivity will benefit both the research and screening markets.

(Logo:  http://photos.prnewswire.com/prnh/20100406/SF82092LOGO)

The SpectraMax Paradigm Detection Platform is the only user upgradeable microplate reader on the market today. It allows the user to read what they want, when they want. Now, with the TUNE detection cartridge, the Paradigm system is the most flexible instrument available. The patent pending Spectral Optimization Wizard in SoftMax® Pro software reduces the assay set up time by more than 50% with simultaneous scanning of excitation and emission spectrums.

Flexibility for Research

For the researchers who need the wavelength flexibility of a monochromator in fluorescent applications, TUNE will offer unmatched sensitivity allowing them to test new assays and further advance their research. The flexibility of the Paradigm platform and ability to easily add future options, makes it a great investment for their labs.

Speed of Paradigm with Sensitivity of TUNE, Ideal for Screening

The TUNE cartridge enables monochromator-like wavelength flexibility without compromising on sensitivity. The Paradigm platform is built with on-the-fly detection for reduced read times, plate format of up to 1536-wells, dual PMTs, and was designed with automation in mind, all important features for high throughput. Use of the TUNE cartridge with the Paradigm instrument will meet the needs of screeners with high sensitivity and
'/>"/>

SOURCE Molecular Devices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens
2. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
3. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
4. Molecular Devices Continues to Lead the Way in Quality Control and Validation Compliance With a New ISO/IEC 17025 Accreditation
5. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
6. Genetix Joins Molecular Devices: Combining Businesses to be in a Better Position to Serve Customers
7. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
8. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
9. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
10. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
11. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , ... once-daily naldemedine met its primary and secondary endpoints in ... of opioid-induced constipation (OIC) in adult patients with chronic ... mu-opioid receptor antagonist (PAMORA). This is the third Phase ... key secondary endpoints. Study results showed that ...
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 /PRNewswire/ ... today announced it received the statistical analysis of results from ... administered in the BVX-005 phase II trial which took place ... which did not exist at the time of the study- ... that caused the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact ... AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation ... an organization whose mission is to develop technology for the sake of humanity ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
(Date:8/3/2015)... ... August 03, 2015 , ... From ... by 39 percent, according to market research compiled for the National Association of ... U.S. Department of Labor, Bureau of Labor Statistics. As the number of dental ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health ... overall performance of the company’s Medicare and Federal Employee Programs (FEP) lines of ... deliver better health for members. In this role, Scott is responsible for overseeing ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical ... least once in their lives. Often time, low back and sciatic pain can happen ... only be managed clinically with powerful pain medication or spinal surgery. Dynamic Health ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2
... opening in September 2009 - ,Those studying in Edinburgh will be able ... provider UNITE opens a brand new development overlooking the Meadows this September ... ... for the new property in Chalmers Street has been opened to give ...
... (MCA) recently honored twelve (12) doctors for their endless dedication to ... those among them who have consistently supported the profession through their ... , ... Dr. Douglas Edwards, Albert Lea, MN , ...
... Breakthrough caregiver training to revolutionize senior home care ... Assistance of Palo Alto, California released its new ... Method(TM). This system, exclusive to Home Care Assistance ... North America with an emphasis on lifestyle, healthy ...
... - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), ... an update on its Phase III clinical program ... On March 31st, the Company announced that recruitment ... registration trial evaluating Urocidin in the treatment of ...
... intrinsic goals is what leads to well-being , , FRIDAY, May ... and fame may sound like a sure ticket to happiness, ... University of Rochester in New York tracked 147 college graduates, ... time -- one year after graduation, and then 12 months ...
... 22 Researchers at Roswell Park Cancer Institute (RPCI) in ... the need to vaccinate both young men and women against ... comes amid growing evidence that certain cancers of the head ... strain of the human papillomavirus (HPV) that is one of ...
Cached Medicine News:Health News:It's Park Life for Edinburgh Students as Unite Unveils New Property Overlooking The Meadows 2Health News:It's Park Life for Edinburgh Students as Unite Unveils New Property Overlooking The Meadows 3Health News:It's Park Life for Edinburgh Students as Unite Unveils New Property Overlooking The Meadows 4Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 2Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 3Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 2Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 3Health News:Looks, Money, Fame Don't Bring Happiness 2Health News:Sexually Transmitted HPV Linked to Certain Head & Neck Cancers 2Health News:Sexually Transmitted HPV Linked to Certain Head & Neck Cancers 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: